ULS_10.2-MED-Conferências
URI permanente para esta coleção:
Navegar
Entradas recentes
- Transforming chronic disease data into actionable knowledge: a comprehensive systematic review for data science models in healthcare knowledge managementPublication . Baptista, Márcia; Vasconcelos, José Braga; Rocha, Álvaro; Silva, Rita; Gouveia, Maria do Carmo Lemos Vieira; Vasconcelos, TiagoThe increasing prevalence of chronic disease, responsible for high mortality and disability, is of considerable concern to healthcare. The ongoing care and management requirements contribute to extreme health costs which affect economies worldwide. Chronic diseases patients require understanding of the existing care models to address their complex and involved health needs. Centers for Disease Control and Prevention shows that providing data to guide, prioritize, deliver and monitor population health is a vital domain to improve Chronic Disease Management. The twenty-first century led to a new age of Data Science and Analytics. Big Data has become a core technology for providing innovative solutions in numerical applications and healthcare services. Embedded in Big Data is valuable information and knowledge. That’s when Data Science becomes an important tool to transform actionable data into knowledge, a requirement to make better decisions, solve complicated problems and optimize health processes. This aims for a Data Science Model as a Healthcare Knowledge Management System tool, which emerges as an important paradigm for innovating healthcare that depends on developing more adaptive, intelligent and user-centric systems that can effectively manage the increasingly dense healthcare knowledge ecosystem. Under this context, there is also a critical need to develop Healthcare Intelligent Systems based on Data Science. This article provides a comprehensive overview of these systems, synthesizing current research and highlighting the critical role of these systems in modern healthcare. It also proposes a model for Healthcare Knowledge Management System based on integrated data science tools transforming healthcare data into actionable knowledge.
- On the run—comparing bioimpedance analysis (BIA) using portable devicesPublication . Dias, Carina Vieira; Dias, Joana C.; Laranjo, Céu; Cardoso, Paulo; De Sousa-Coelho, Ana LuísaBioelectrical impedance analysis (BIA) is a non-invasive indirect method that allows for measurement of lean and fat body mass. The main goal of this exploratory study was to compare the results from two different portable BIA devices. We found that only fat-free mass and body fat mass were directly comparable between InBodyS10 (Teprel, Porto, Portugal) and seca mBCA 525 (Bacelar, Porto, Portugal) medical portable BIA devices.
- Report of a rare 3q29 interstitial microdeletion: prenatal diagnosis and postnatal follow-upPublication . Simão, Laurentino; Pedro, Sónia; Marques, Bárbara; Serafim, Sílvia; Ferreira, Cristina; Tarelho, Ana; Brito, Filomena; Silva, Marisa; Alves, Cristina; Viegas, Mónica; Silva, Ana Paula; Rodrigues, Márcia; Ferreira, Ângela; Correia, HildebertoDistal interstitial deletions in the 3q29 region are rare. The characterization of new prenatal diagnosis (PND) cases and their follow-up may add knowledge about the affected region.
- Is preoperative chemosensitivity associated with improved outcomes in locally advanced gastric cancer? A multicentric retrospective real-world studyPublication . Caleça, T.; Honório, M.; Sousa, M.; Ribeiro, J.; Fortuna, A.; Silva, D. Neto da; Albuquerque, J.; Menezes, M.; Trabulo, C.; Costa, D.Perioperative chemotherapy (PCT) is the standard of care for locally advanced gastric cancer (LAGC) in western countries. However, less than 60% of patients complete the adjuvant part of treatment due to postoperative complications, toxicity and disease progression (DP). This study aim is to evaluate if preoperative chemosensitivity (POCS) is associated with improved overall survival (OS) and disease free survival (DFS).
- Nephrotic syndrome in pregnant diabetic women: maternal and perinatal outcomes at a tertiary centerPublication . Nogueira, Estela; Afonso, Rita; Godinho, Iolanda; Centeno, Mónica; Pinto, Luísa; Lopes, José AntónioManagement of pregnant women with diabetic kidney disease and nephrotic range proteinuria or nephrotic syndrome constitute a challenge to clinicians. Maternal and perinatal outcomes, especially in patients with chronic kidney disease, remain poor. The authors describe the multidisciplinary approach and the outcomes of diabetic pregnant patients with nephrotic range proteinuria.
- Adalimumab and number of previous biological disease-modifying antirheumatic drugs as predictive factors for the development of immune-mediated skin lesionsPublication . Martins, A.; Oliveira, D. Santos; Martins, F. R.; Nicolau, R.; Pinheiro, F. Oliveira; Rato, M.; Bernardo, A.; Pimenta, S.; Bernardes, M.; Costa, L.Treatment of inflammatory rheumatic diseases has dramatically changed with the introduction of biologic disease modifying anti-rheumatic drugs (bDMARDs). However, these drugs aren’t exempt from risks and skin lesions are the most frequent adverse reactions. Among the possible adverse skin reactions, immune-mediated skin lesions (IMSL) may occur. Risk factors associated with the occurrence of IMSL in rheumatic patients under bDMARDs are poorly known and studied.
- Immune-mediated skin lesions related to biological disease-modifying antirheumatic drugs: a 22-year experience of a tertiary centerPublication . Martins, A.; Oliveira, D. Santos; Martins, F. R.; Nicolau, R.; Pinheiro, F. Oliveira; Rato, M.; Bernardo, A.; Pimenta, S.; Bernardes, M.; Costa, L.Biological disease-modifying antirheumatic drugs (bDMARDs) have revolutionized the treatment of chronic inflammatory rheumatic diseases. However, the physician and the patient should be aware of possible adverse reactions. Skin is one of the most frequent organs involved in bDMARD adverse reactions and immune-mediated skin lesions (IMSL) have rarely been described before in cohort studies and their incidence is unknown.
- Neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio are not predictive of pathologic complete response to neoadjuvant chemotherapy in triple-negative breast cancerPublication . Pinho, I. Soares de; Barroso, T.; Trabulo, C.; Campoa, E.; Patel, V.; Gonçalves, L.; Araújo, J.; Monteiro, C.; Ferreira, A.; Machado, B.; Dâmaso, S.; Luz, P.; Sousa, R. Teixeira de; Costa, L.Pathological complete response (pCR) to neoadjuvant chemotherapy (NAChT) has been validated as a predictor of long-term survival in breast cancer (BC), especially in triple-negative breast cancer (TNBC)
- Maintaining remission after an episode of steroid-responsive acute severe ulcerative colitis: what is the best strategy?Publication . Bravo, C.; Gomes, C. Frias; Blesl, A.; Damasceno, J.; Drygiannakis, I.; Argyriou, K.; Festa, S.; Aratari, A.; Todeschini, A.; Jelakovic, M.; Kani, H. Tarik; Idrees, Z.; Feijó, D.; Chaves, C.; Bacsur, P.; Michalopoulos, G.; Turcan, S.; Nardone, O. M.; Spyridon, V.; Bernardi, A. De; Nagmeldin, I.; Denjagic, M. Basic; Ribaldone, D. Giuseppe; Ploutarchos, P.; Karakan, T.; Oliveira, R.; Balestrieri, P.; Lopes, S.; Vasilakis, T.; Taelman, T.; Neri, B.; Clarke, M.; Mocci, G.; Kiudelis, G.; Vieujean, S.; Sciberras, N.; Milenkovic, Z.; Bonazzi, E.; Karmiris, K.; Torres, J.The best maintenance therapy after a steroid-responsive acute severe ulcerative colitis (ASUC) episode remains poorly studied and is not addressed in current guidelines. We aimed to compare the impact of different treatment strategies following hospitalization for steroid-responsive ASUC.
- Fidaxomicin for Clostridiodes difficile infection in inflammatory bowel disease: a multicenter retrospective cohort studyPublication . Noviello, D.; Chaparro, M.; Viganò, C.; Blesl, A.; Barberio, B.; Yanai, H.; Macaluso, F.; Iglesias, R. Ferreiro; Bezzio, C.; Zilli, A.; Molnár, T.; Gheorghe, C.; Conforti, F. S.; Innocenti, T.; Saibeni, S.; Bossuyt, P.; Oliveira, R. F. de; Gabrielli, A. M. Carvalhas; Losco, A.; Vieujean, S.; Tettoni, E.; Pirola, L.; Calderone, S.; Cohen, M. Kornowski; Dragoni, G.; Rath, T.; Acosta, M. Barreiro-de; Savarino, E. V.; Gisbert, J. P.; Vecchi, M.; Atreya, R.; Caprioli, F.Inflammatory bowel disease (IBD) patients with Clostridiodes difficile Infection (CDI) are at increased risk of disease exacerbations, therapy escalation, colectomy, and mortality. Data on fidaxomicin use in IBD patients with CDI are very limited. We aimed to assess the effectiveness and safety of fidaxomicin for CDI and its impact on IBD outcomes in a large retrospective multicenter cohort study